脂质体作为药物输送中的纳米载体已受到重视，市场上的产品数量正在稳步增加，特别是在癌症治疗领域。在脂质体中远程装载药物是第一个脂质体产品的转化和商业化的重要一步。低载药量和脂质体药物渗漏是一个转化障碍，但远程装载过程有效地克服了这一障碍。远程装载或主动装载可以装载近 100% 的药物，这是被动装载程序不可能实现的。传统远程装载的一个主要缺点是只有极少数的药物适合这种方法。因此，载药方法对于多种药物来说仍然是一个问题。最近，随着一种可提高急性髓系白血病总体生存率的市售制剂（Vyxeos）的推出，在脂质体中装载多种药物以提高纳米药物的功效和安全性已引起人们的关注。这里讨论修改远程加载过程以克服传统方法的缺点的不同策略。该综述旨在讨论远程装载技术的最新发展及其对脂质体药物递送的影响。

Liposomes have gained prominence as nanocarriers in drug delivery, and the number of products in the market is increasing steadily, particularly in cancer therapeutics. Remote loading of drugs in liposomes is a significant step in the translation and commercialization of the first liposomal product. Low drug loading and drug leakage from liposomes is a translational hurdle that was effectively circumvented by the remote loading process. Remote loading or active loading could load nearly 100% of the drug, which was not possible with the passive loading procedure. A major drawback of conventional remote loading is that only a very small percentage of the drugs are amenable to this method. Therefore, methods for drug loading are still a problem for several drugs. The loading of multiple drugs in liposomes to improve the efficacy and safety of nanomedicine has gained prominence recently with the introduction of a marketed formulation (Vyxeos) that improves overall survival in acute myeloid leukemia. Different strategies for modifying the remote loading process to overcome the drawbacks of the conventional method are discussed here. The review aims to discuss the latest developments in remote loading technology and its implications in liposomal drug delivery.